Senseonics Holdings, Inc. 8-K

What Happened

• Senseonics Holdings, Inc. (through Senseonics, Incorporated and related buyer parties) announced it entered Local Asset Purchase Agreements with Ascensia Diabetes Care Holdings AG on March 12, 2026 to acquire commercial assets related to the Eversense continuous glucose monitor (CGM) business in four European territories: Italy, Germany, Spain and Sweden.
• These Local Purchase Agreements implement a Master Asset Purchase Agreement originally executed December 31, 2025. Each European asset purchase is expected to close on or before June 30, 2026, subject to customary closing conditions.

Key Details

• Parties: Purchaser Parties (Senseonics Holdings and affiliates) and Seller Parties (Ascensia and affiliates).
• Closing timing: European Closings expected on or before June 30, 2026.
• Purchase price mechanics: At each European Closing, Senseonics will pay Ascensia the Net Book Value of the applicable purchased assets, subject to terms in the Master and Local Purchase Agreements.
• Transition Services Agreement: Ascensia will provide transition support (logistics, IT, finance, claims processing, regulatory support, employee transition) generally through June 30, 2026, for agreed service fees payable by Senseonics.

Why It Matters

• The transactions transfer commercial responsibility for Eversense in four European markets from Ascensia to Senseonics, expanding Senseonics’ direct commercial footprint in Europe. For investors, this could affect Senseonics’ revenue mix, operating costs (including transition and assumption of liabilities), and execution risk tied to regulatory consents, tender contract transfers and employee transitions. The deals are conditional on regulatory clearances, consents and customary closing conditions; payments are based on Net Book Value rather than a fixed headline price. The filing includes forward‑looking statement cautions about timing, costs and risks.